Bizarre Patents
An extension member is attachable to a trailer hitch and extends away from the vehicle and is connected to a seating frame supporting a toilet seat.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8058406 | Composition comprising antibodies to LINGO or fragments thereof Endogenous LINGO-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-1 function, such anti-LINGO-1 antibodies can be used as therapeutics for the treatment of neur... | 11/15/2011 |
| 7777010 | Use of a native epitope for selecting evolved binding members from a library of mutants of a protein capable of binding to said epitope The invention provides a method for selecting at least one member from a library of proteinaceous molecules by providing at least one cell and/or a functional equivalent thereof, with at least part of the library under conditions that allow binding of any such membe... | 08/17/2010 |
| 7772375 | Monoclonal antibodies that recognize epitopes of amyloid-beta The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abn... | 08/10/2010 |
| 7592430 | Antibodies to M-CSF The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions t... | 09/22/2009 |
| 7524939 | Antibodies that bind to and inhibit human cytochrome P450 2C9*1, 2C9*2, and 2C9*3 The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C8, 2C9, 2C18, and 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of the various human cytochrome P450 2C family members... | 04/28/2009 |
| 7435797 | Anti-HER2 antibody variants The present invention concerns novel antibody variants, particularly anti-HER2 antibody variants having substitutions at positions within the variable domains of the heavy and light chains ... | 10/14/2008 |
| RE40535 | Anti-KC4 humanized monoclonal antibody and cells that express the antibody An anti-KC-4 humanized monoclonal antibody that comprises the variable regions of the light and heavy chains of the anti-KC-4 murine antibody, wherein the light chain has 7 amino acids and the heavy chain has 12 amino acids of the framework regions substituted with ... | 10/07/2008 |
| 7431926 | Tumor supressor gene p33ING2 The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods ... | 10/07/2008 |
| 7432359 | Anti-A33 antibody The present invention provides: an antibody or a antibody fragment thereof, which can bind to A33, which specifically attacks A33-expressing tumor cells with the use of ADCC and CDC based on the immune system, and for which no HAHA is produced; and a preventive or t... | 10/07/2008 |
| 7422739 | Anti-CD20 antibodies Disclosed are chimeric, immunologically active, isolated, and radiolabeled antibodies directed against the CD20 antigen. The antibodies are useful for treating and diagnosing B cell disorders. ... | 09/09/2008 |
| 7420039 | Individualized anti-cancer antibodies The present invention relates to a method for producing patient specific anti-cancer antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production o... | 09/02/2008 |
| 7408041 | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-de... | 08/05/2008 |
| 7387772 | Chimeric, human and humanized anti-CSAP monoclonal antibodies The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer. ... | 06/17/2008 |
| 7381803 | Humanized antibodies against CD3 The invention provides bispecific antibodies with selective cytotoxicity against malignant B-cells. The bispecific antibodies bind to an effector cell antigen and to a 28/32 kDa heterodimeric protein on the surface of malignant B-cells. The invention also includes t... | 06/03/2008 |
| 7375193 | Anti-VEGF antibodies Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo. ... | 05/20/2008 |
| 7371723 | Therapeutic agents comprising pro-apoptotic proteins The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-induc... | 05/13/2008 |
| 7368111 | Human antibodies specific for TGFβ2 Specific binding members comprising human antibody antigen binding domains specific for human transforming growth factor beta (TGFβ) bind specifically isoforms TGFβ2 and TGFβ1 or both, preferentially compared with TGFβ3. Specific binding members may be isolated ... | 05/06/2008 |
| 7364863 | Monoclonal antibody W8B2 and method of use The invention relates to a monoclonal antibody, or fragments thereof, for isolating and/or identifying mesenchymal stem cells. In this connection, the antibody, or fragments thereof, bind to an antigen which is the same as that bound to by an antibody which is produ... | 04/29/2008 |
| 7361336 | Methods of cancer therapy targeted against a cancer stem line Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer t... | 04/22/2008 |
| 7354762 | Method for producing CE7-specific redirected immune cells Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular signaling domain, and a transmembrane domain, and methods of use for such ... | 04/08/2008 |
| 7348412 | Ouabain-specific monoclonal antibodies The invention relates to a monoclonal antibody or antigen binding fragment thereof having binding specificity for ouabain, wherein the antibody or antigen binding fragment does not crossreact with digoxin. Preferably the anti-ouabain monoclonal antibody can bind oua... | 03/25/2008 |
| 7341722 | Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-EGP-2 scFv fragment The present invention relates to a method for stabilizing chimeric immunoglobulins or immunoglobulin fragments. Furthermore, the invention also provides a stabilized anti-EGP-2 scFv fragment. ... | 03/11/2008 |
| 7335747 | Cancer associated gene mina 53, protein Mina 53 and monoclonal antibody thereof Myc protein is an unevenly distributed intermediate agent for cell proliferation, and activates a gene expression via E.box. Mina53 gene encodes a protein of 53 kDa molecular weight and is present in the nucleoplasm and nucleolus. Mina53 mRNA and protein expression ... | 02/26/2008 |
| 7321881 | Methods and systems for predicting occurrence of an event Embodiments of the present invention are directed to methods and systems for training a neural network having weighted connections for classification of data, as well as embodiments corresponding to the use of such a neural network for the classification of data, in... | 01/22/2008 |
| 7319139 | TAG-72 specific C2 domain deleted antibodies Methods, compositions and kits comprising dimeric antibodies for the treatment of neoplastic, autoimmune or other disorders are provided. The dimeric antibodies of the instant invention may comprise two antibody molecules (H4L4) having the same... | 01/15/2008 |
| 7312320 | Neutralizing antibodies and methods of use thereof This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using t... | 12/25/2007 |
| 7297334 | Anti-vegf antibodies Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo. ... | 11/20/2007 |
| 7288637 | Single chain antibody against mutant p53 More than 90% of mutations found in the p53 protein produce a conformational change in p53 which results in the exposure of an epitope, which is otherwise hidden in the hydrophobic core of the molecule. A single chain antibody (scFv) which specifically recognizes th... | 10/30/2007 |
| 7285635 | Modified proteins, designer toxins, and methods of making thereof The present invention concerns methods of reducing the antigenicity of a proteinaceous compound while maintaining the compounds biological activity, as well as proteinaceous compositions with biological activity but reduced antigenicity. These methods and compositio... | 10/23/2007 |
| 7279160 | Combinations of DR5 antibodies and other therapeutic agents An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination w... | 10/09/2007 |
| 7265209 | CE7-specific chimeric T cell receptor Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular signaling domain, and a transmembrane domain, and methods of use for such ... | 09/04/2007 |
| 7250494 | Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria The present invention encompasses monoclonal antibodies that bind to lipoteichoic acid (LTA) of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro. The invention also provides antibodies h... | 07/31/2007 |
| 7238785 | RS7 antibodies This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an e... | 07/03/2007 |
| 7232887 | Melanoma antigens and their use in diagnostic and therapeutic methods The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, asses... | 06/19/2007 |
| 7230086 | Assay for YKL-40 as a marker for degradation of mammalian connective tissue matrices The invention is a method of identifying the presence of a disease state in a mammal which is associated with degradation of connective tissue in the mammal which contains the protein known as YKL-40. The method is a competitive immunoassay for YKL-40. It can be use... | 06/12/2007 |
| 7227002 | Human antibodies that bind human 17-A1/EpCAM tumor antigen The present invention provides an anti-human antibody or fragment thereof that is low or not immunogenic in humans. In particular, the antibodies or fragments are directed to human tumor antigens, preferably to the human tumor antigen 17-1A, also known as EpCAM, EGP... | 06/05/2007 |
| 7220838 | Antibodies that specifically bind hedgehog-derived polypeptides The present invention provides two novel polypeptides, referred to as the “N” and “C” fragments of hedgehog, or N-terminal and C-terminal fragments, respectively, which are derived after specific cleavage at a G↓CF site recognized by the autopro... | 05/22/2007 |
| 7217532 | Methods for detecting DNA damage and screening for cancer therapeutics A method for detecting DNA damage in a tissue sample involves contacting an immobilized biological sample with a labeled ligand which binds to human 53Bp1, and examining the immobilized sample for the presence of a label generated-detectable signal concentrated in f... | 05/15/2007 |
| 7211644 | Diagnostic markers of human female infertility Methods and reagents for the diagnosis of female infertility, prognostic indicators for female infertility, compounds for the treatment of female infertility, compounds and methods for contraception. Methods and compounds are based on the levels of ebaf in endometri... | 05/01/2007 |
| 7202346 | Antibodies to non-shed Muc1 and Muc16, and uses thereof The present invention relates to antibodies, antibody fragments, conjugates of antibodies and antibody fragments with cytotoxic agents, and hybridomas producing the antibodies and antibody fragments, where the antibodies and antibody fragments recognize extracellula... | 04/10/2007 |
